These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3116031)

  • 41. The rapid ovarian secretory response to pituitary stimulation by the gonadotropin-releasing hormone agonist nafarelin in sexual precocity.
    Rosenfield RL; Garibaldi LR; Moll GW; Watson AC; Burstein S
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1386-9. PubMed ID: 2946712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of endometriosis with domestic luteinizing hormone--releasing hormone analogue].
    Geng L; Gu FY; Zhang LZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):592-4, 636. PubMed ID: 7712871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome.
    Dodson WC; Hughes CL; Whitesides DB; Haney AF
    J Clin Endocrinol Metab; 1987 Jul; 65(1):95-100. PubMed ID: 2953752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
    Spinder T; Spijkstra JJ; van den Tweel JG; Burger CW; van Kessel H; Hompes PG; Gooren LJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):151-7. PubMed ID: 2471710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women.
    Meldrum DR; Tsao Z; Monroe SE; Braunstein GD; Sladek J; Lu JK; Vale W; Rivier J; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1984 Apr; 58(4):755-7. PubMed ID: 6365947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease.
    Toscano V; Balducci R; Bianchi P; Mangiantini A; Sciarra F
    J Clin Endocrinol Metab; 1990 Aug; 71(2):288-92. PubMed ID: 2166066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.
    Lobo RA; Granger L; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1981 Jan; 52(1):156-8. PubMed ID: 6778890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
    Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
    Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome.
    Gilling-Smith C; Story H; Rogers V; Franks S
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):93-9. PubMed ID: 9302378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease.
    DeFazio J; Meldrum DR; Lu JK; Vale WW; Rivier JE; Judd HL; Chang RJ
    Fertil Steril; 1985 Oct; 44(4):453-9. PubMed ID: 3932097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum 11 beta-hydroxyandrostenedione as an indicator of the source of excess androgen production in women with polycystic ovaries.
    Polson DW; Reed MJ; Franks S; Scanlon MJ; James VH
    J Clin Endocrinol Metab; 1988 May; 66(5):946-50. PubMed ID: 3129451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.